1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Fuso Pharmaceutical Industries,Ltd.

Fuso Pharmaceutical Industries,Ltd.

4538.T
Fuso Pharmaceutical Industries,Ltd.JP flagTokyo Stock Exchange
2,161.00
JPY
+21.00
- -
18.45BMarket Cap
Fuso Pharmaceutical Industries,Ltd.
4538.T
(Tokyo Stock Exchange)

Recent

price

2,161.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
5,240.84
4,898.6
5,365.87
5,424.58
5,199.66
5,058.75
5,206.51
5,186.38
5,249.41
5,344.98
5,613.77
5,657.78
5,816.28
6,434.65
7,089.44
7,297.09
3,278.59
Revenue per Share
126.3
41.08
538.01
218.66
37.58
1.11
95.83
109.6
101.86
80.57
183.16
169.05
182.99
159.92
-384.9
235.52
77.33
Basic EPS, GAAP
654.59
-35.56
146.9
136.34
-65.77
-353.27
-31.16
-33.56
-30.42
367.41
230.24
229.24
145.82
-343.88
-749.54
-923.22
- -
Free Cash Flow per Basic Share
59.84
59.85
59.87
89.72
79.8
79.72
79.8
79.77
79.76
69.86
59.84
59.85
59.86
74.91
74.68
85.96
- -
Dividend per Share
1,891.25
1,872.84
2,461.98
2,578.16
2,550.09
2,472.1
718.63
1,971.39
2,057.93
2,071.46
2,196.7
2,301.44
2,424.9
2,554.88
2,115.29
2,264.89
3,343.5
Book Value per Share
2,877.39
2,918.98
3,690.65
3,816.74
3,664.25
3,565.19
3,565.46
3,567.75
3,656.12
3,622.01
3,802.43
3,884.71
4,026.88
4,187.99
3,690.81
3,947.37
4,332.39
Tangible Book Value per Share
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
Basic Weighted Avg Shares
47,469
44,358
48,581
49,096
47,042
45,752
46,781
45,900
46,073
46,902
49,253
49,632
51,015
55,406
60,562
62,307
27,982
Sales/Revenue/Turnover
4.57
1.08
7.83
5.69
1.69
0.65
1.4
1.74
2.74
2.16
4.78
3.88
4.33
3.54
6.82
4.24
3.09
Operating Margin (%)
2,088
1,888
1,750
1,878
1,914
1,513
2,004
1,921
1,967
2,381
2,410
2,559
2,486
2,263
2,354
2,618
- -
Depreciation Expense
1,144
372
4,871
1,979
340
10
861
970
894
707
1,607
1,483
1,605
1,377
-3,288
2,011
660
Net Income, GAAP
- -
- -
21.89
25.29
47.7
91.45
18.85
28.73
28.76
32.15
31.43
22.34
27.17
22.01
- -
17.47
10.92
Effective Tax Rate (%)
2.41
0.84
10.03
4.03
0.72
0.02
1.84
2.11
1.94
1.51
3.26
2.99
3.15
2.49
-5.43
3.23
2.36
Profit Margin (%)
6,810
7,842
13,358
14,337
11,001
10,631
12,312
11,836
11,960
12,310
12,770
13,412
14,745
15,297
4,211
5,652
12,295
Working Capital
5,736
6,679
6,195
5,165
5,138
8,226
8,292
8,913
9,391
8,245
6,640
5,758
5,747
7,021
2,462
1,858
2,777
LT Debt
26,263
26,598
33,789
34,892
33,538
32,616
32,545
32,580
32,842
32,301
33,684
34,531
35,649
36,661
33,043
35,057
37,900
Total Equity
- -
- -
6.63
4.33
0.84
0.05
1.06
1.18
1.81
1.4
3.39
3.17
3.37
3.08
- -
3.66
1.51
Return on Invested Capital (%)
- -
- -
15.26
6.05
1.19
0.07
3.29
4.12
3.07
2.51
5.3
5
5.21
4.34
- -
5.24
1.78
Return on Capital (%)
6.8
2.18
24.82
8.68
1.47
0.04
5.98
8.12
5.04
3.9
8.58
7.52
7.74
6.36
-16.41
10.75
2.38
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
6,690
- -
11,027
LT Borrowings
7,021
- -
2,777
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
- -
9
Market Capitalization
19,303
20,859
19,178

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
44,947
- -
45,371
Cash, Cash Equivalents & STI
5,120
- -
4,617
Accounts Receivable, Net
24,328
- -
25,735
Inventories
14,202
- -
14,261
Total Current Liabilities
29,650
- -
33,076
Payables & Accruals
- -
- -
- -
ST Debt
6,690
- -
11,027
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.81%
0.96%
6.1%
Free Cash Flow
-166.91%
-45.8%
23.11%
Net Income, GAAP
810.76%
-102.73%
-161.16%
Sales/Revenue/Turnover
3.19%
4.87%
2.88%
Total Cash Common Dividend
- -
- -
15.05%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,507
13,917
15,406
12,576
55,406
2025
- -
- -
- -
- -
60,562
2026
- -
- -
- -
- -
62,307

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
54.62
- -
- -
- -
159.92
2025
- -
- -
- -
- -
-384.9
2026
- -
- -
- -
- -
235.52

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
74.91
2025
- -
- -
- -
- -
74.68
2026
- -
- -
- -
- -
85.96
Similar Companies
4Front Ventures Corp. (FFVWF)
Medicine Man Technologies, Inc. (SHWZ)
Catalent, Inc. (CTLT)
CENTR Brands Corp. (CNTR.CN)
Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070.SR)
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (002864.SZ)
Business
Fuso Pharmaceutical Industries, Ltd. manufactures and sells pharmaceuticals, medical equipment, and related products primarily in Japan. The company offers a comprehensive range of injectables including glucose, maltose, xylitol, fructose, Ringer's solution, isotonic sodium chloride, and maintenance fluids such as Hartmann-G3, VEEN-3G, and Klinisalz infusions; dialysis agents and solutions for artificial kidneys including powder dialysate, Heparin Sodium for dialysis, and hemodialysis solutions; ethical drugs, diagnostic reagents, research reagents, and assisted reproductive technology products such as culture media for in vitro fertilization like HFF99; vitamins and metabolic agents including B-Six, Plevita S, and combinations of thiamine, ascorbic acid, pyridoxine; and other specialized pharmaceuticals like nalfurafine, procaine hydrochloride (Rocain), atropine sulfate, carbazochrome sodium sulfonate, parnaparin sodium, icosapent ethyl, and polystyrene sulfonates; alongside medical devices and contract manufacturing of drugs, with real estate leasing as a secondary business. Founded in 1937 and headquartered at 1-7-10 Doshomachi, Chuo-ku, Osaka, Japan, it operates factories including Joto, Okayama, Daito, and Ibaraki, employs 1,340 people, and lists on the Prime Market of the Tokyo Stock Exchange (4538). Recent developments include expansion of powder dialysate production for hemodialysis at the Ibaraki Factory's second formulation building in January 2024; and in January 2025, an exclusive development and license agreement with Dimerix Limited for DMX-200, a Phase 3 candidate for focal segmental glomerulosclerosis in Japan, featuring an upfront payment of ¥300 million, potential milestones up to ¥10.5 billion, and royalties of 15-20%, with Fuso funding Japanese clinical trials and regulatory submissions.